2-Hydroxyglutarate in IDH Mutant Acute Myeloid Leukemia: Predicting Patient Responses, Minimal Residual Disease and Correlations with Methylcytosine and Hydroxymethylcytosine Levels

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2012 Jun 12

PMID 22680765

Citations 9

Authors

Daniel A Pollyea

Holbrook E Kohrt

Bing Zhang

James Zehnder

David Schenkein

Valeria Fantin

Kimberly Straley

Aparna Vasanthakumar

Omar Abdel-Wahab

Ross Levine

Lucy A Godley

Bruno C Medeiros

Affiliations

Soon will be listed here.

Citing Articles

Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite.

Berger R, Wachsmuth C, Waldhier M, Renner-Sattler K, Thomas S, Chaturvedi A Cancers (Basel). 2021; 13(8).

PMID: 33916994 PMC: 8067704. DOI: 10.3390/cancers13081756.

Clinical relevance of mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Ferret Y, Boissel N, Helevaut N, Madic J, Nibourel O, Marceau-Renaut A Haematologica. 2018; 103(5):822-829.

PMID: 29472349 PMC: 5927984. DOI: 10.3324/haematol.2017.183525.

Targeting minimal residual disease: a path to cure?.

Luskin M, Murakami M, Manalis S, Weinstock D Nat Rev Cancer. 2018; 18(4):255-263.

PMID: 29376520 PMC: 6398166. DOI: 10.1038/nrc.2017.125.

Quantitative Imaging of D-2-Hydroxyglutarate in Selected Histological Tissue Areas by a Novel Bioluminescence Technique.

Voelxen N, Walenta S, Proescholdt M, Dettmer K, Pusch S, Mueller-Klieser W Front Oncol. 2016; 6:46.

PMID: 27014623 PMC: 4779886. DOI: 10.3389/fonc.2016.00046.

Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Al-Hussaini M, Dipersio J Expert Rev Hematol. 2014; 7(4):439-64.

PMID: 25025370 PMC: 4283573. DOI: 10.1586/17474086.2014.932687.

References

Ito S, DAlessio A, Taranova O, Hong K, Sowers L, Zhang Y . Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. 2010; 466(7310):1129-33. PMC: 3491567. DOI: 10.1038/nature09303. View

Pronier E, Almire C, Mokrani H, Vasanthakumar A, Simon A, da Costa Reis Monte Mor B . Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood. 2011; 118(9):2551-5. PMC: 3292425. DOI: 10.1182/blood-2010-12-324707. View

Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. PMC: 2818760. DOI: 10.1038/nature08617. View

Figueroa M, Abdel-Wahab O, Lu C, Ward P, Patel J, Shih A . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18(6):553-67. PMC: 4105845. DOI: 10.1016/j.ccr.2010.11.015. View

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S . Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19(1):17-30. PMC: 3229304. DOI: 10.1016/j.ccr.2010.12.014. View